|
[Related PubMed/MEDLINE]
Total Number of Papers: 49
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: CR |
| Long Form |
: complete remission rate |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2019 |
Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia. |
AML, FLAG |
| 2 |
2019 |
Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China. |
GDP, MA, MTX, ORR, OS, PTCL |
| 3 |
2019 |
The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma. |
ENKTL, OS, PFS, ROC |
| 4 |
2019 |
Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas. |
DFS, ICT, LAHNSCC, OS, RCT, TPF |
| 5 |
2019 |
[Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center]. |
ASCT, MM, OS, TRM, TTP, VGPR |
| 6 |
2018 |
Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study. |
ORR, OS |
| 7 |
2018 |
Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience. |
AML, AML-MRC, HMA, IC, OS |
| 8 |
2017 |
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). |
CI, HR, LDH, OS, PFS, RP, T-PLL |
| 9 |
2017 |
Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. |
ENKTL, OS, P-GEMOX, PFS, PR, RT |
| 10 |
2017 |
Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis. |
CBM, CNIs, eGFR, PR, SCr |
| 11 |
2016 |
Comparison of MACT and 5Fu+ACT-D chemotherapy regimens in the treatment of low-risk gestational trophoblastic neoplasia. |
5-FU, ActD, LR-GTN, MTX |
| 12 |
2016 |
The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era. |
allo-SCT, ASCT, BMT, FL, OS, PFS, TRM |
| 13 |
2016 |
[Comparison of Clinical Outcomes between P190 and P210 Trans-cripts in Adult Ph Chromosome Positive Acute Lymphoblastic Leukemia in the New Era of TKI]. |
HSCT, TKI |
| 14 |
2016 |
[Expression and Prognostic Significance of H3K27 Trimethylation Protein in DLBCL]. |
DLBCL, H3K27me3, IHC, OR, TMA |
| 15 |
2015 |
Combination treatment with antiEGFR monoclonal antibodies in advanced nasopharyngeal carcinoma : a meta-analysis. |
MFS, NPC, RCTs |
| 16 |
2015 |
[Clinical and prognostic analysis of 30 cases of primary central nervous system lymphoma]. |
OS, PCNSL, PFS, SRS, WBRT |
| 17 |
2015 |
[Efficacy Analysis of MAC Regimen as Salvage Treatment Protocol for Acute Myeloid Leukemia Patients Older Than 55 Years]. |
AML, ORR, OS, PR, PR, RFS |
| 18 |
2014 |
Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. |
AML, CI, HR, OS, RFS |
| 19 |
2014 |
Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). |
PFS-6 |
| 20 |
2014 |
Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma. |
ASCT, OS, PFS |
| 21 |
2012 |
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. |
AML, OS |
| 22 |
2012 |
The role of decitabine for the treatment of acute myeloid leukemia. |
AML |
| 23 |
2012 |
[Clinical and laboratory features of pediatric acute myeloid leukemia with inversion of chromosome 16]. |
AML, CBFbeta, D-FISH |
| 24 |
2011 |
[Central nervous system lymphoma and its significance]. |
CNSL, IPI, PR |
| 25 |
2011 |
[Detection of WT1 gene in acute myeloid leukemia children by real-time fluorescent quantitative RT-PCR and its clinical significance]. |
AML, OS, RT-PCR |
| 26 |
2011 |
[Efficacy of radiofrequency hyperthermia combined with chemotherapy in treatment of malignant pericardial effusion caused by lung cancer]. |
combined therapy group, RR |
| 27 |
2010 |
[Analysis of outocome of pirarubicin-based combination chemotherapy regimen in the treatment of newly diagnosed acute myeloid leukemia-a prospective, open, randomized and multicenter clinical trial]. |
AML, DA, TRR |
| 28 |
2010 |
[Role of dendritic cells and their Toll-like receptor 4 in the pathogenesis of idiopathic thrombocytopenic purpura]. |
DC, ITP, n-CR, TLR4 |
| 29 |
2009 |
[ABVD chemotherapy scheme at day 1 and 8 for treatment of primary Hodgkin's lymphomas]. |
ABVD, DFS, HL |
| 30 |
2008 |
Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience. |
ALL, AML, HSCT |
| 31 |
2006 |
Treatment of Hodgkin's disease: a twenty-year follow-up of patients at a center in Korea. |
DFS, HD, OS |
| 32 |
2006 |
[Expression of Ki-67 and Bcl-2 in adults and children with acute lymphoblastic leukemia and its clinical significance]. |
ALL |
| 33 |
2005 |
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. |
BR |
| 34 |
2004 |
Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. |
AML, CNS, EMI |
| 35 |
2004 |
Treatment of atypical neurocytomas. |
CR-RT, IR, IR-RT |
| 36 |
1998 |
Outcome in Hodgkin's disease: a 20-year cohort of patients. |
BNLI |
| 37 |
1996 |
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG. |
AML |
| 38 |
1996 |
Aggressive non-Hodgkin's lymphoma: long-term results of full dose CHOP chemotherapy, and analysis of prognostic determinant. |
--- |
| 39 |
1994 |
[Simultaneous radiochemotherapy in locoregional recurrent breast carcinoma after mastectomy. Results in patients with macroscopic residual tumor R2]. |
--- |
| 40 |
1992 |
Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy. |
ALL, AML, BMT, ID Ara-C, NHL, PR |
| 41 |
1992 |
Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. |
AML, MPO, TLD |
| 42 |
1991 |
Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL. |
NHL, PR |
| 43 |
1989 |
Acute promyelocytic leukemia: a 5-year experience with new antileukemic agents and a new approach to preventing fatal hemorrhage. |
FFP |
| 44 |
1989 |
Treatment of childhood acute lymphoblastic leukemia with protocol TCL821: a report of Taiwan Children's Cancer Study Group. |
6-MP, ADM, ALL, Ara-C, CCR, CNS, MTX, PRED, VCR |
| 45 |
1986 |
[Clinical features and treatment results in 88 children with malignant lymphoma]. |
PR |
| 46 |
1983 |
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). |
--- |
| 47 |
1982 |
Prognostic value of age and bone marrow karyotype in 78 adults with acute myelogenous leukemia. |
AML |
| 48 |
1980 |
Methotrexate/L-asparaginase combination chemotherapy for patients with acute leukemia in relapse: a study of 36 children. |
ALL, ANLL, CML, L-ASP, MTX, TdT |
| 49 |
1976 |
The use of the Robinson in vitro agar culture assay in adult acute leukemia. |
--- |
|
A Search Service for Abbreviation / Long Form
